Brenda Irwin’s Post

View profile for Brenda Irwin, graphic

Managing General Partner @ Relentless Venture Fund | Health Technology Venture Capital

Excellent way to spend 1 minute, 30 seconds. DSO shares via an embedded video in the article below how Modality.AI is making an impact with patients. It is wonderful to have NIH SEED as a partner on this journey. Relentless Venture Fund David "DSO" Suendermann-Oeft #Neurotech #AI #BIO2024 #precisionmedicine #clinicaltrials #healthtech #healthcare #digitalhealth

View organization page for NIH SEED, graphic

3,415 followers

NIH SEED is proud to share a #BIO2024 article featuring an interview with Modality.AI’s CEO and Founder David "DSO" Suendermann-Oeft. “Today, Modality is used exclusively in clinical trials to help bring new treatments to the market, and enable researchers to better understand diseases, especially in neurology and psychiatry. ... By expanding into healthcare in the future, Modality.AI will help address the urgent need for better neurological and psychiatric care combined with precision medicine.” Many thanks to Biotechnology Innovation Organization's Clary Estes for this excellent write-up! #SBIR #STTR https://lnkd.in/g3zMRgPf

NIH Innovation Zone 2024: Modality.AI tackles remote neurological assessment

NIH Innovation Zone 2024: Modality.AI tackles remote neurological assessment

https://bio.news

To view or add a comment, sign in

Explore topics